Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

CONCLUSIONS: Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.PMID:37831547 | DOI:10.1080/15384047.2023.2265055

Source: Cancer Biology and Therapy - October 13, 2023 Category: Cancer & Oncology Authors: Aihua Tan Li Nong Hongxue Wang Yuxian Jia Wuning Zhong Fanghui Qin Han Wang Jing Tang Yan Liu Yongkui Lu Source Type: research